pepstatin and Erythema

pepstatin has been researched along with Erythema* in 1 studies

Other Studies

1 other study(ies) available for pepstatin and Erythema

ArticleYear
In vitro secreted aspartyl proteinase activity of Candida albicans isolated from oral diseases and healthy oral cavities.
    Oral microbiology and immunology, 2003, Volume: 18, Issue:6

    The in vitro secreted aspartyl proteinase (SAP) activity of Candida albicans isolated from a variety of oral conditions, including healthy oral cavities, was determined. SAP activity (units/10(6) cells/ml, +/-SD) was 0.28 +/- 0.33 for pseudomembranous candidosis isolates (n = 18), 0.35 +/- 0.46 for chronic erythematous candidosis isolates (n = 21) and 0.30 +/- 0.32 for chronic hyperplastic candidosis isolates (n = 50). SAP activity of 0.19 +/- 0.22 was recorded for isolates from squamous cell carcinoma (n = 18), 0.26 +/- 0.37 for burning mouth syndrome isolates (n = 29), 0.25 +/- 0.38 for isolates from xerostomia (n = 15) and 0.39 +/- 0.50 for isolates from lichen planus (n = 13). The SAP activity of isolates from oral disease states was significantly (P < 0.05) higher than that recorded for 28 isolates from healthy mouths (activity of 0.04 +/- 0.03). However, there was no significant difference in the SAP activity between the three forms of clinical oral candidosis (P > 0.05). SAP activity was inhibited in control samples containing the SAP inhibitor, pepstatin A. These results indicate that C. albicans strains associated with oral disease have inherently higher SAP activity.

    Topics: Aspartic Acid Endopeptidases; Burning Mouth Syndrome; Candida albicans; Candidiasis, Oral; Carcinoma, Squamous Cell; Chronic Disease; Erythema; Humans; Hyperplasia; Lichen Planus, Oral; Mouth Diseases; Mouth Neoplasms; Pepstatins; Protease Inhibitors; Xerostomia

2003